HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Probiotic Skin Care Could Be Gutsy Move In US Regulatory Environment

This article was originally published in The Rose Sheet

Executive Summary

Findings that oral probiotics may not only benefit digestive health but also potentially alleviate inflammatory skin disorders are contentious but have driven uptake of probiotic ingredients by cosmetic players. Market opportunity is growing, but probiotic skin-care claims could be liabilities in the US where FDA increasingly has been citing statements about immunotherapeutic and anti-inflammatory effects in warning letters.

Advertisement

Related Content

FDA Says Probiotic Cosmetics Could Be Adulterated, ‘Good’ Bacteria Or Not
Probiotic Mother Dirt Joins Brands Touting 'Made Safe' Certification
FDA’s July Warning Letters To Skin-Care Marketers Continue To Surface
FDA Warning Letter Barrage Continues With Five More To Close July
Dermatologist Foresees Rise In Topical Probiotic Acne Treatments

Topics

Advertisement
UsernamePublicRestriction

Register

RS108618

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel